NASDAQ:AXDX Accelerate Diagnostics (AXDX) Stock Price, News & Analysis $3.92 -0.08 (-2.00%) (As of 12/29/2023 ET) Add Compare Share Share Today's Range$3.72▼$4.0550-Day Range$3.92▼$6.3852-Week Range$3.72▼$11.90Volume105,552 shsAverage Volume46,136 shsMarket Capitalization$57.04 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Accelerate Diagnostics MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestBearish5.13% of Float Sold ShortDividend StrengthN/ASustainability-1.62Upright™ Environmental ScoreNews Sentiment1.44Based on 2 Articles This WeekInsider TradingSelling Shares$8,509 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($4.63) to ($2.03) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.08 out of 5 starsMedical Sector549th out of 950 stocksAnalytical Instruments Industry13th out of 26 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Accelerate Diagnostics. Previous Next 2.0 Short Interest Percentage of Shares Shorted5.13% of the float of Accelerate Diagnostics has been sold short.Short Interest Ratio / Days to CoverAccelerate Diagnostics has a short interest ratio ("days to cover") of 13.9, which indicates bearish sentiment.Change versus previous monthShort interest in Accelerate Diagnostics has recently decreased by 10.02%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAccelerate Diagnostics does not currently pay a dividend.Dividend GrowthAccelerate Diagnostics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAccelerate Diagnostics has received a 74.73% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Diagnostic test kits" product. See details.Environmental SustainabilityThe Environmental Impact score for Accelerate Diagnostics is -1.62. Previous Next 4.1 News and Social Media Coverage News SentimentAccelerate Diagnostics has a news sentiment score of 1.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.84 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Accelerate Diagnostics this week, compared to 1 article on an average week.Search Interest1 people have searched for AXDX on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Accelerate Diagnostics to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Accelerate Diagnostics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,509.00 in company stock.Percentage Held by Insiders33.00% of the stock of Accelerate Diagnostics is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Accelerate Diagnostics are expected to grow in the coming year, from ($4.63) to ($2.03) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Accelerate Diagnostics is -0.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Accelerate Diagnostics is -0.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Accelerate Diagnostics Stock (NASDAQ:AXDX)Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. The company was incorporated in 1982 and is headquartered in Tucson, Arizona.Read More AXDX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AXDX Stock News HeadlinesNovember 22, 2023 | finance.yahoo.comAccelerate Diagnostics (AXDX) Loses -25.65% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerNovember 11, 2023 | finance.yahoo.comAccelerate Diagnostics, Inc. (NASDAQ:AXDX) Q3 2023 Earnings Call TranscriptDecember 31, 2023 | MarketBeat Internal (Ad)New Year's Sale: Get MarketBeat All Access Free For 30 DaysAccess our premier research platform that includes MarketBeat Daily Premium, portfolio monitoring tools, stock screeners, research tools, a real-time news feed, email and SMS alerts, the MarketBeat Idea Engine, proprietary brokerage rankings, extended data export tools and much more. Click the link to claim your $300.00 account credit and free 30-day subscriptionNovember 10, 2023 | finanznachrichten.deAccelerate Diagnostics, Inc.: Accelerate Diagnostics Reports Third Quarter 2023 ResultsNovember 10, 2023 | seekingalpha.comAccelerate Diagnostics, Inc. (AXDX) Q3 2023 Earnings Call TranscriptNovember 9, 2023 | finance.yahoo.comAccelerate Diagnostics Reports Third Quarter 2023 ResultsOctober 30, 2023 | finance.yahoo.comAccelerate Diagnostics Scheduled Call to Review 2023 Third Quarter Results.October 3, 2023 | businesswire.comAccelerate Investor Conference Reveals 2023 Keynote Speakers and PanelistsDecember 31, 2023 | Behind the Markets (Ad)New Year's Sale: Get 12 Months of Stock Picks for $9.00Gear up for what's happening in the stock market in 2024. Our friends at Behind the Markets are offering an opportunity that is simply too good to pass up - 12-months of their best stock ideas for just $9.00. Don't sleep on this. October 3, 2023 | finance.yahoo.comAccelerate Diagnostics (AXDX) Moves 12.7% Higher: Will This Strength Last?September 14, 2023 | finance.yahoo.comInsider Sell: CEO Jack Phillips Sells 733 Shares of Accelerate Diagnostics IncAugust 11, 2023 | finanznachrichten.deAccelerate Diagnostics, Inc.: Accelerate Diagnostics Reports Second Quarter 2023 Financial ResultsAugust 11, 2023 | markets.businessinsider.comAccelerate Diagnostics Reports Second Quarter 2023 Financial ResultsAugust 8, 2023 | markets.businessinsider.comCraig-Hallum Reaffirms Their Hold Rating on Accelerate Diagnostics (AXDX)July 28, 2023 | finance.yahoo.comAccelerate Diagnostics Scheduled Call to Review 2023 Second Quarter ResultsJuly 12, 2023 | finanznachrichten.deAccelerate Diagnostics, Inc.: Accelerate Diagnostics Announces 1-for-10 Reverse Stock SplitJuly 11, 2023 | bizjournals.comAccelerate Diagnostics Inc. to undergo 1-for-10 reverse stock splitJuly 10, 2023 | msn.comAccelerate Diagnostics to implement 1-for-10 reverse share splitJuly 10, 2023 | finance.yahoo.comAccelerate Diagnostics Announces 1-for-10 Reverse Stock SplitJuly 6, 2023 | msn.comAccelerate Diagnostics (AXDX) Price Target Increased by 50.00% to 0.92June 13, 2023 | finance.yahoo.comIndividual investors invested in Accelerate Diagnostics, Inc. (NASDAQ:AXDX) up 45% last week, insiders too were rewardedMay 12, 2023 | finanznachrichten.deAccelerate Diagnostics, Inc.: Accelerate Diagnostics Reports First Quarter 2023 Financial ResultsMay 11, 2023 | msn.comRecap: Accelerate Diagnostics Q1 EarningsMay 11, 2023 | finance.yahoo.comAccelerate Diagnostics Reports First Quarter 2023 Financial ResultsMay 11, 2023 | finance.yahoo.comSyneos Health (SYNH) Announces a $7.1 Billion Merger AgreementMay 10, 2023 | markets.businessinsider.comAccelerate Diagnostics is about to announce its earnings — here's what Wall Street expectsApril 27, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Repligen (RGEN), SurModics (SRDX) and Accelerate Diagnostics (AXDX)See More Headlines Receive AXDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Accelerate Diagnostics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2023Today12/31/2023Fiscal Year End12/31/2023Next Earnings (Estimated)4/03/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Analytical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AXDX CUSIPN/A CIK727207 Webacceleratediagnostics.com Phone(520) 365-3100Fax520-269-6580Employees179Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($5.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-62,490,000.00 Net Margins-472.05% Pretax Margin-522.81% Return on EquityN/A Return on Assets-137.08% Debt Debt-to-Equity RatioN/A Current Ratio0.86 Quick Ratio0.76 Sales & Book Value Annual Sales$12.00 million Price / Sales4.75 Cash FlowN/A Price / Cash FlowN/A Book Value($2.25) per share Price / Book-1.74Miscellaneous Outstanding Shares14,551,000Free Float9,749,000Market Cap$57.04 million OptionableOptionable Beta0.92 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Jack Phillips (Age 57)CEO, President & Director Comp: $595kMr. Lawrence Michael Mertz (Age 61)Chief Technology Officer Comp: $329.23kMr. Steve Reichling (Age 45)Consultant Comp: $349.81kMr. David Patience (Age 37)CFO, Principal Financial Officer & Principal Accounting Officer Ms. Maya GowriSenior VP & Head of OperationsLaura PiersonInvestor Relations OfficerMs. Gretchen StrohmingerSenior VP and Head of Human Resources & CultureMr. John MeduriChief Strategy OfficerMr. Kurtis MontegnaSenior Vice President of Regulatory Affairs & Quality AssuranceMr. Chris ThodeSenior Vice President of US CommercialMore ExecutivesKey CompetitorsBerkeley LightsNASDAQ:BLICue HealthNASDAQ:HLTHBionano GenomicsNASDAQ:BNGORapid Micro BiosystemsNASDAQ:RPIDSingular Genomics SystemsNASDAQ:OMICView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Sold 2,595,294 shares on 12/18/2023Ownership: 2.083%Jack PhillipsSold 739 sharesTotal: $3,244.21 ($4.39/share)David PatienceSold 97 sharesTotal: $425.83 ($4.39/share)Belpointe Asset Management LLCSold 307,430 shares on 11/16/2023Ownership: 0.235%Tudor Investment Corp Et AlSold 127,028 shares on 11/16/2023Ownership: 0.097%View All Insider TransactionsView All Institutional Transactions AXDX Stock Analysis - Frequently Asked Questions How have AXDX shares performed in 2023? Accelerate Diagnostics' stock was trading at $7.06 at the start of the year. Since then, AXDX stock has decreased by 44.5% and is now trading at $3.92. View the best growth stocks for 2023 here. When is Accelerate Diagnostics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 3rd 2024. View our AXDX earnings forecast. How were Accelerate Diagnostics' earnings last quarter? Accelerate Diagnostics, Inc. (NASDAQ:AXDX) posted its quarterly earnings data on Thursday, November, 9th. The medical research company reported ($0.92) earnings per share for the quarter, topping the consensus estimate of ($0.94) by $0.02. The medical research company earned $3.30 million during the quarter, compared to the consensus estimate of $3.60 million. When did Accelerate Diagnostics' stock split? Shares of Accelerate Diagnostics reverse split on the morning of Wednesday, July 12th 2023. The 1-10 reverse split was announced on Wednesday, July 12th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of Accelerate Diagnostics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Accelerate Diagnostics investors own include Himax Technologies (HIMX), Magnachip Semiconductor (MX), Fluidigm (FLDM), Universal Display (OLED), Gilead Sciences (GILD), BIOLASE (BIOL), Alibaba Group (BABA), AT&T (T), AbbVie (ABBV) and Micron Technology (MU). How do I buy shares of Accelerate Diagnostics? Shares of AXDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AXDX) was last updated on 12/31/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Accelerate Diagnostics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.